|
名稱
|
Mouse GM-CSF / CSF2 Protein/重組小鼠 GM-CSF / CSF2
|
|
規(guī)格
|
20ug
|
|
編號
|
CZDB-002
|
|
價格
|
詢價
|
|
中文名
|
重組小鼠 GM-CSF / CSF2 蛋白
|
|
分子別稱
|
AI661682, ATAC, LTN, Lptn, SCM-1, SCM-1a, Scyc1
|
|
分子種屬
|
Mouse
|
|
表達標簽
|
His，S
|
|
表達宿主
|
E. coli
|
|
濃度
|
> 95 % as determined by SDS-PAGE
|
|
緩沖液
|
Lyophilized from sterile PBS, pH 7.4
|
|
存儲條件
|
-70°C，應避免反復凍融。
|
|
基本描述
|
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is one of an array of cytokines with pivotal roles in embryo implantation and subsequent development. Several cell lineages in the reproductive tract and gestational tissues synthesise GM-CSF under direction by ovarian steroid hormones and signalling agents originating in male seminal fluid and the conceptus. The pre-implantation embryo, invading placental trophoblast cells and the abundant populations of leukocytes controlling maternal immune tolerance are all subject to GM-CSF regulation. GM-CSF stimulates the differentiation of hematopoietic progenitors to monocytes and neutrophils, and reduces the risk for febrile neutropenia in cancer patients. GM-CSF also has been shown to induce the differentiation of myeloid dendritic cells (DCs) that promote the development of T-helper type 1 (cellular) immune responses in cognate T cells. The active form of the protein is found extracellularly as a homodimer, and the encoding gene is localized to a related gene cluster at chromosome region 5q31 which is known to be associated with 5q-syndrome and acute myelogenous leukemia. As a part of the immune/inflammatory cascade, GM-CSF promotes Th1 biased immune response, angiogenesis, allergic inflammation, and the development of autoimmunity, and thus worthy of consideration for therapeutic target. GM-CSF has been utilized in the clinical management of multiple disease processes. Most recently, GM-CSF has been incorporated into the treatment of malignancies as a sole therapy, as well as a vaccine adjuvant. While the benefits of GM-CSF in this arena have been promising, recent reports have suggested the potential for GM-CSF to induce immune suppression and, thus, negatively impact outcomes in the management of cancer patients. GM-CSF deficiency in pregnancy adversely impacts fetal and placental development, as well as progeny viability and growth after birth, highlighting this cytokine as a central maternal determinant of pregnancy outcome with clinical relevance in human fertility.
|
